Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer

NCT ID: NCT01701349

Last Updated: 2014-05-01

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE3
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-31
• Study Completion Date: 2017-12-31

Brief Summary

This is a multicenter, double-blind, placebo-controlled, randomized study of fosbretabulin given with chemotherapy (paclitaxel and carboplatin) compared to placebo given with chemotherapy (paclitaxel and carboplatin) in subjects with anaplastic thyroid cancer (ATC). The primary objective of the study is to determine overall survival. A maximum of 300 subjects will be recruited from approximately 75 multinational sites of which approximately 35 will be located in the United States.

Detailed Description

The Treatment Plan followed for all subjects will consist of:

• A Screening Visit within 14 days before study drug (fosbretabulin or placebo) administration
• A Treatment Phase of 21-day combination treatment (study drug plus chemotherapy) cycles (up to 6 cycles)
• An End of Treatment Phase assessment
• An End of Study Visit occurring 30 days after the last day of study drug administration, as able

After the last clinic visit, all subjects will be followed for survival by monthly phone calls, email, or in-person.

Conditions

Anaplastic Thyroid Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Fosbretabulin + paclitaxel + carboplatin

Six 21 day cycles of:

Fosbretabulin (60 mg/m2) IV on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC 6) IV on Day 2

Group Type: ACTIVE_COMPARATOR

Fosbretabulin + paclitaxel + carboplatin

Intervention Type: DRUG

Fosbretabulin 200 mg/m2 IV infusion

Placebo + paclitaxel + carboplatin

Six 21-day cycles of:

Placebo (formulated and packages to match fosbretabulin)on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC6) IV on Day 2

Group Type: PLACEBO_COMPARATOR

Placebo + paclitaxel + carboplatin

Intervention Type: DRUG

Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion

Interventions

Fosbretabulin + paclitaxel + carboplatin

Fosbretabulin 200 mg/m2 IV infusion

Intervention Type: DRUG

Placebo + paclitaxel + carboplatin

Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion

Intervention Type: DRUG

Other Intervention Names

Fosbretabulin; Combretastatin; Zybrestat; CA4P; Paclitaxel; Carboplatin

Eligibility Criteria

Inclusion Criteria

• Unresectable, residual, recurrent or persistent ATC, histologically or cytologically confirmed
• Prior cytotoxic therapeutic regimen as primary therapy for curative intent or prior targeted therapies (TKIs) are eligible (Prior taxane or platinum therapy is allowed)
• Untreated ATC following biopsy, surgery for curative intent, palliation, or after radiation therapy has been considered or administered with or without radiosensitizing chemotherapy
• Disease present on clinical exam (measurable or non-measurable)
• Distant metastases (Stage IVC) only must have histologic confirmation of ATC either from the original primary lesion or a metastatic site
• Neoadjuvant therapy with radiation and either radiosensitizing chemotherapy followed by surgery for curative intent, palliation, or biopsy are eligible if residual or persistent ATC is present
• Subjects with tracheostomy are eligible
• ECOG PS 2 or less
• Adequate bone marrow, renal, and hepatic function, electrolytes WNL for the institution

Exclusion Criteria

• Disease that is able to be completely resected with negative microscopic margins and without any residual disease in the body
• Active brain metastases, including symptomatic involvement, evidence of cerebral edema by prior CT or MRI, radiographic evidence of brain metastasis since definitive therapy, or continued requirement for corticosteroids for cerebral edema
• History of malignancies other than ACT except prior lower grade thyroid malignancy, curatively treated basal cell carcinoma and in-situ melanoma of the skin, cervical intra-epithelial neoplasia,localized prostate cancer, in-situ carcinoma of the breast
• Known intolerance or hypersensitivity to fosbretabulin, paclitaxel, carboplatin or any of their components
• Receiving concurrent investigational therapy or have received investigational therapy for any indication within 28 days of the first scheduled day of dosing
• Grade 3 or greater peripheral neuropathy
• History of prior cerebrovascular event,including transient ischemic attack within the past 6 months
• Uncontrolled hypertension defined as blood pressure >150/100 mm Hg despite medication
• Symptomatic vascular disease (e.g. intermittent claudication)
• History of unstable angina pectoris pattern, myocardial infarction (including non-Q wave) within the past 6 months, or NYHA Class III or IV congestive heart failure
• History of torsade de pointes, ventricular tachycardia, ventricular fibrillation or congenital long QT syndrome.
• Pathologic bradycardia (<60 b/m or heart block(excluding 1st degree block, consisting of PR interval prolongation only)
• ECG findings of clinically significant ventricular arrhythmia, new ST segment elevation or depression, or new Q wave on ECG (PVCs are not excluded).
• QTc interval 480 ms or more
• Requirement of concurrent treatment with any drugs know to prolong the QTc interval, including anti-arrhythmic medications
• Potassium and/or magnesium concentrations below normal range for the reference laboratory
• History of solid organ or bone marrow transplant

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mateon Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Marcia Brose, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania, Philadelphia, PA 19104

Julie A Sosa, MD

Role: PRINCIPAL_INVESTIGATOR

Yale University, New Haven, CT 06520

Lisa Licitra, MD

Role: PRINCIPAL_INVESTIGATOR

Instituto Nazionale Per Lo Studio E La Cura Dei Tumori, Milan, Italy

Related Links

http://thyca.org

Thyroid Cancer Survivors' Association, Inc.

Other Identifiers

OX4317s

Identifier Type: -

Identifier Source: org_study_id